We are very proud to announce that our head of Strategy and BD&L, Nikki Hafezi, MASIP ETHZ, has been voted onto the “Top 40 under 40” list 2015 by her peers.
Ophthalmica.gr holds a press conference on the opening of the LfS21 Reference Center in Thessaloniki.
Nikki Hafezi gives a guide to turning bright ideas into commercial realities
The concept of using photoactivated chromophores for corneal cross-linking (PACK-CXL) as a weapon against infectious keratitis is compelling
Infectious keratitis is a leading cause of global blindness, with an estimated 5 million new cases occurring every year in developing countries
EMAGine SA, a spin-off company from the University of Geneva and co-founded by Nikki and Farhad Hafezi, is elected amongst the best start-ups in Switzerland in 2014
An optimized treatment protocol, a miniaturized device that mounts on a slit lamp and a new photosensitizing agent may allow for a faster and more effective application of cross-linking for infectious keratitis in the near future.
Read here (Article in Portuguese).
Read here (Article in Slovenian).
Keratoconus is extremely frequent in Down Syndrome
